Clinical Trial

Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-01.
Trial Details
NCT Number NCT05897957
Lead Sponsor BlueRock Therapeutics
Conditions Parkinson Disease
Enrollment 12 participants
Start Date 2023-05-16
Primary Completion 2027-05 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2024-04-12